case_images: PMC9797826_01
case_images: Complete timeline for treatment regimens, disease status and patient treatment response.
case_images: fonc-12-1071383-g001.jpg
case_images: PMC9797826_01_fonc-12-1071383-g001.jpg
case_images: f1
case_images: NCCN guideline, we gave the patient post-operative chemotherapy, and the timeline of the treatment process is shown in  Figure 1 . No tumor was detected by CT after 6 cycles of TP/TC therapy (175 mg/m2 paclitaxel plus 75/mg2 cisplatin, or 175 mg/m2 paclitaxel plus carboplatin area under the curve (AUC) 5), so she was considered to have achieved complete clinical response (CR).
case_images: MRI images of local recurrent lesions during treatment. (A) Local recurrence of the last progression (January 2019). (B) MRI images after the last 6 cycles of non-platinum-based chemotherapy combined with bevacizumab (July 2021). (C) MRI images of 12 months after maintenance treatment using the PARP inhibitor Olaparib (July 2022).
case_images: fonc-12-1071383-g002.jpg
case_images: PMC9797826_01_fonc-12-1071383-g002.jpg
case_images: f2
case_images: Magnetic resonance imaging (MRI) and [18F] fluorodeoxyglucose (FDG) -positron emission tomography (PET) showed that there was a mass on the right side of the vaginal stump and the right posterior rectal wall, accompanied by increased glucose metabolism ( Figure 2A ). In  Figure 2 , we display the radiographic changes occurred in our patient during treatment.
case_images: Three-dimensional conformal dose assessment for interstitial BT. (A). Cross-sectional image. (B). Sagittal image. (C). Coronal image. (D). Dose-volume histogram (DVH).
case_images: fonc-12-1071383-g003.jpg
case_images: PMC9797826_01_fonc-12-1071383-g003.jpg
case_images: f3
case_images: Figure 3  shows the three-dimensional conformal dose assessment for interstitial brachytherapy. Following the completion of radiotherapy, the patient received individual therapy with PARP inhibitor (olaparib) for maintenance due to homologous recombination deficiency (HRD).
case_images: Changes in serum CA125 and HE4 levels during the whole process of treatment.
case_images: fonc-12-1071383-g004.jpg
case_images: PMC9797826_01_fonc-12-1071383-g004.jpg
case_images: f4
case_images: Currently, the patient remained in CR at the last imaging follow-up in July 2022, even though tumor markers (serum CA125 and HE4) had started to slowly increase ( Figure 4 ).